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Results: Of the 463 patients, 209 received CFRT and 254 
received HFRT. Median age was 48yrs (IQR:40-
56),premenopausal(CFRT:23%vs HFRT 39%,p=0.005), and LABC 
presentation(CFRT36% vs HFRT 52%, p=0.01) was seen in 
higher proportion of patients receiving HFRT. The commonest 
pathology was IDC (81%) with grade III tumors (45%),ER (+) 
was seen in 44%,TNBC in 34% and Her2Neu (3+) were seen in 
27%. 254 patients(54.5%)had undergone BCS and 209 patients 
(45%) MRM. 54% had left sided cancer and neoadjuvant 
chemotherapy(NACT) was given in 38%.The grade, HR status, 
laterality, NACT administration, BCS/MRM were similar in the 
2 arms. For MRM patients, enface electrons were used in 88% 
patients treated with CFRT and 76% patients with HFRT. LN 
RT was delivered in 76% vs 64% in patients receiving CFRT vs 
HFRT respectively (p=0.005). With a median follow-up of 
40mo in CFRT (IQR:14-55) and 29 mo in HFRT (IQR 17-38 ), 
9/209 (4.3%) patients in CFRT and 7/254 (2.7%) in HFRT had 
LR .On univariate analyses, the 2yr actuarial LRFS in CFRT vs 
HFRT was 95% vs 97% (p=0.37). The 2yr OS in CFRT vs HFRT 
was 81% vs 85%(p=0.035) and 2year DDFS was 80% vs 83 % 
(p=0.15)respectively.  
 
Conclusion: The risk of local recurrence among patients of 
breast cancer treated with HFRT after BCS or MRM was not 
worse when compared to conventional radiation therapy 
despite a younger population with locally advanced clinical 
presentation in HFRT. 
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Purpose or Objective: This investigation retrospectively 
compared early-stage breast cancer patients treated with 
accelerated hypofractionation (AHF) to the age- and stage-
matched patients treated with conventional fractionation 
(CF). 
 
Material and Methods: Three hundred seventy-nine early-
stage (pT1-2 and pN0-1a) breast cancer patients who 
received radiation therapy (RT) with AHF after breast-
conserving surgery (BCS) were included. These patients were 
matched by the years in which BCS was performed, age (±3 
years), and stage to the 379 corresponding patients in a 
different center, who received BCS and RT with CF. The AFH 
regimen was delivered as 39Gy in 13 fractions to the whole 
breast and consecutive 9-12Gy in 3-4 fractions to the tumor 
bed. The CF was composed of whole breast irradiation up to 
50.4Gy in 28 fractions and then boost to the lumpectomy 
cavity with 9-14Gy in 5-7 fractions. 
 
Results: The median follow-up time was 75 months (range: 
3.8-110.8 months). There was no statistically significant 
difference in the age, T and N stage, resection margin, and 
histologic grade. There were five ipsilateral breast tumor 
relapse (IBTR) in the AHF group compared with seven in the 
CF group. Seven and eight loco-regional relapse (LRR) was 
observed in the AHF and the CF group, respectively. The 7-
year rates of IBTR-free survival (IBTRFS), LRR-free survival 
(LRRFS), and disease-free survival (DFS) were 98.9%, 98.4%, 
and 97.1% in the AHF arm and 98.1%, 97.9% and 96.0% in the 
CF arm, respectively (p > 0.05). Among AHF patients, no risk 
factors including histologic grade or molecular subtype were 
associated with IBTR. The incidences of mild, grade 1 edema, 
hyperpigmentation, and wet desquamation at the end of RT 
were observed higher in the CF group. 
 
Conclusion: While reducing fraction number, AHF 
radiotherapy of 39Gy whole breast plus 9Gy boost in 16 
fractions is comparable to CF radiotherapy with excellent 
tumor control and tolerable skin toxicity in patients with 
early-stage breast cancer. 
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Purpose or Objective: Hypofractionated whole breast 
irradiation (HF-WBI) following breast conserving surgery has 
produced excellent outcomes, but utilization remains 
limited. We evaluated the impact of the landmark study 
(START) in the adoption of HF-WBI in Sun Yat-Sen Cancer 
Center (KFSYSCC) at Taiwan. 
 
Material and Methods: Information was obtained from the 
institutional breast cancer data base with stage I to III breast 
cancer receiving adjuvant whole-breast radiotherapy 
between 2012 and Aug 2015. Patients treated with palliative 
intent, accelerated partial breast radiation were excluded. 
HF-WBI was defined as ≤21 fractions with a dose/fraction 
≥2.5 Gy. 
 
 
 
Results: We identified 1042 patients meeting inclusion 
criteria. HF-WBI utilization increased significantly from 4% 
before July 2013 to 57% afterwards. The adoption of HF-WBI 
reach 77% since July 2015. The reimbursement structure here 
is based on “course” rather than “number” of treatment, the 
increased adoption of HF-WBI saved an estimated $700,000 
annually in our Cancer Center. 
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Conclusion: We found that the publication of START A and B 
trials in 2013 substantially increased adoption of HF-WBI for 
breast cancer at KFSYSCC , which increased the use of HF-
WBI by 19-fold. The reimbursement structure allow us to 
quick adopt state of art and standard care for early stage 
breast cancer. 
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Purpose or Objective: The aim of the study was to report 
quality of life and others aspects based on EORTC 
questionnaire intraoperative radiotherapy (IORT) given as a 
boost during breast conserving surgery (BCS) followed by 
adjuvant whole breast radiotherapy (WBRT).  
 
Material and Methods: Between 2008 and 2011 in 150 breast 
cancers patients treated in Greater Poland Cancer Centre. 
Intraoperative radiotherapy as a tumor bed boost was applied 
using mobile electron accelerator Mobetron 1000 (IntraOp 
Medical, Inc.). IORT boost (10 Gy) was followed by 50 Gy 
whole-breast external beam radiotherapy (EBRT). 
Chemotherapy, if indicated, was given before EBRT. The 
observation period was 1,5-5,5 years. The data was assessed 
by EORTC questionnaires (QLQ-C30 and QLQ-BR23) 1 month 
after RT, 6 months, 1 year, 2 years, 3 years and 4 years. 
 
Results : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab 1. QLQ-C30 questionnaire data 
 
There was no statistical significance change in quality of life 
in any follow-up period based on Friedman test analysis 
(p=0,2143).  
 
Tab 2. QLQ-BR23 questionnaire data 
 
There was statistical significance change in body image 
between 1 and 6 months after radiation therapy (p=0,008), 
but it was lower than EORTC reference score. Sexual 
enjoyment was lower than EORTC reference score in any 
follow up period time. Systemic therapy side effects was 
higher than EORTC control group in any follow up period 
time. 
 
Conclusion: Intraoperative radiotherapy is proved to be 
tolerable and perspective treatment procedure with no 
statistical significance influence on quality of life. 
